Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA, Fecher LA, Owens SR, Razumilava N. Nadeau BA, et al. Among authors: fecher la. Semin Liver Dis. 2018 Nov;38(4):366-378. doi: 10.1055/s-0038-1667358. Epub 2018 Oct 24. Semin Liver Dis. 2018. PMID: 30357774 Review.
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Bishu S, et al. Among authors: fecher la. Gastroenterology. 2021 Feb;160(3):932-934.e3. doi: 10.1053/j.gastro.2020.10.029. Epub 2020 Oct 21. Gastroenterology. 2021. PMID: 33096100 Free PMC article. No abstract available.
Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ, Ma VT, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Sankar K, Ramnath N, Lao C, Sussman JB, Fecher L, Alva A, Green MD. Waninger JJ, et al. JAMA Netw Open. 2021 Mar 1;4(3):e210980. doi: 10.1001/jamanetworkopen.2021.0980. JAMA Netw Open. 2021. PMID: 33687443 Free PMC article.
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Santomasso BD, et al. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724386
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Schneider BJ, et al. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724392
72 results